Ki-Chul Hwang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ki-Chul Hwang has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Heesang Song
Department of Pediatrics, Washington University in St. Louis School of Medicine, 606 S. Euclid Ave. St. Louis, MO 63108, USA
3 shared publications- Woochul Chang
Department of Biology Education, College of Education, Pusan National University, Busan, Korea
3 shared publications Hakbae Lee
Department of Applied Statistics, Yonsei University, Seoul, Korea
2 shared publicationsNamsik Chung
Yonsei University Medical College, Cardiology, Seoul, Korea
2 shared publications- Seok-Min Kang
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
2 shared publications Soyeon Lim
Cardiovascular Research Institute, Cardiology Division, Department of Internal Medicine, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, 120-752, South Korea
2 shared publications
Latest Publications
- 31 August 2008
- Published by Elsevier in European Journal of Pharmacology
- Vol. 597 (1-3) , 64-69
Cordycepin inhibits vascular smooth muscle cell proliferation
- 31 August 2008
- Published by Elsevier in European Journal of Pharmacology
- Vol. 597 (1-3) , 64-69
Cordycepin inhibits vascular smooth muscle cell proliferation
- 31 August 2007
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 13 (6) , S33-33
Losartan Inhibits Proliferation and Inflammation of Uric Acid-stimulated Vascular Smooth Muscle Cells by Modulation of Uric Acid Transporter
- 31 August 2007
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 13 (6) , S33-33
Losartan Inhibits Proliferation and Inflammation of Uric Acid-stimulated Vascular Smooth Muscle Cells by Modulation of Uric Acid Transporter
- Open Access
- 8 March 2007
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 25 (6) , 1431-1438
Tissue Transglutaminase Is Essential for Integrin-Mediated Survival of Bone Marrow-Derived Mesenchymal Stem Cells
Autologous mesenchymal stem cell (MSC) transplantation therapy for repair of myocardial injury has inherent limitations due to the poor viability of the stem cells after cell transplantation. Adhesion is a prerequisite for cell survival and also a key factor for the differentiation of MSCs. As a novel prosurvival modification strategy, we genetically engineered MSCs to overexpress tissue transglutaminase (tTG), with intention to enhance adhesion and ultimately cell survival after implantation. tTG-transfected MSCs (tTG-MSCs) showed a 2.7-fold and greater than a twofold increase of tTG expression and surface tTG activity, respectively, leading to a 20% increased adhesion of MSCs on fibronectin (Fn). Spreading and migration of tTG-MSCs were increased 4.75% and 2.52%, respectively. Adhesion of tTG-MSCs on cardiogel, a cardiac fibroblast-derived three-dimensional matrix, showed a 33.1% increase. Downregulation of tTG by transfection of small interfering RNA specific to the tTG resulted in markedly decreased adhesion and spread of MSCs on Fn or cardiogel. tTG-MSCs on Fn significantly increased phosphorylation of focal adhesion related kinases FAK, Src, and PI3K. tTG-MSCs showed significant retention in infarcted myocardium by forming a focal adhesion complex and developed into cardiac myocyte-like cells by the expression of cardiac-specific proteins. Transplantation of 1 × 106 MSCs transduced with tTG into the ischemic rat myocardium restored normalized systolic and diastolic cardiac function. tTG-MSCs further restored cardiac function of infarcted myocardium as compared with MSC transplantation alone. These findings suggested that tTG may play an important role in integrin-mediated adhesion of MSCs in implanted tissues.Disclosure of potential conflicts of interest is found at the end of this article.
- 8 March 2007
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 25 (6) , 1431-1438
Open AccessTissue Transglutaminase Is Essential for Integrin-Mediated Survival of Bone Marrow-Derived Mesenchymal Stem Cells
Autologous mesenchymal stem cell (MSC) transplantation therapy for repair of myocardial injury has inherent limitations due to the poor viability of the stem cells after cell transplantation. Adhesion is a prerequisite for cell survival and also a key factor for the differentiation of MSCs. As a novel prosurvival modification strategy, we genetically engineered MSCs to overexpress tissue transglutaminase (tTG), with intention to enhance adhesion and ultimately cell survival after implantation. tTG-transfected MSCs (tTG-MSCs) showed a 2.7-fold and greater than a twofold increase of tTG expression and surface tTG activity, respectively, leading to a 20% increased adhesion of MSCs on fibronectin (Fn). Spreading and migration of tTG-MSCs were increased 4.75% and 2.52%, respectively. Adhesion of tTG-MSCs on cardiogel, a cardiac fibroblast-derived three-dimensional matrix, showed a 33.1% increase. Downregulation of tTG by transfection of small interfering RNA specific to the tTG resulted in markedly decreased adhesion and spread of MSCs on Fn or cardiogel. tTG-MSCs on Fn significantly increased phosphorylation of focal adhesion related kinases FAK, Src, and PI3K. tTG-MSCs showed significant retention in infarcted myocardium by forming a focal adhesion complex and developed into cardiac myocyte-like cells by the expression of cardiac-specific proteins. Transplantation of 1 × 106 MSCs transduced with tTG into the ischemic rat myocardium restored normalized systolic and diastolic cardiac function. tTG-MSCs further restored cardiac function of infarcted myocardium as compared with MSC transplantation alone. These findings suggested that tTG may play an important role in integrin-mediated adhesion of MSCs in implanted tissues.Disclosure of potential conflicts of interest is found at the end of this article.
- 5 December 2003
- Published by Elsevier in European Journal of Pharmacology
- Vol. 484 (2-3) , 119-125
Antiproliferative mechanisms of raxofelast (IRFI-016) in H2O2-stimulated rat aortic smooth muscle cells
- 5 December 2003
- Published by Elsevier in European Journal of Pharmacology
- Vol. 484 (2-3) , 119-125
Antiproliferative mechanisms of raxofelast (IRFI-016) in H2O2-stimulated rat aortic smooth muscle cells